Zynex Announces Award of UK Patent for Non-Invasive Detection of Sepsis
Zynex (NASDAQ: ZYXI) has secured UK patent 2617515 for a novel multiparameter, noninvasive sepsis monitoring device. The technology aims to address a critical global health crisis, as sepsis affects 1.7 million people annually in the US alone and causes 11 million deaths globally, with one-third of hospital deaths being sepsis-related.
The device will continuously monitor physiological signals to provide early alerts about patient sepsis status, leveraging Zynex's cardiac monitoring expertise. Early detection is crucial for patient recovery, as highlighted by the Surviving Sepsis Campaign. The technology could significantly impact treatment outcomes, particularly considering that over 50% of sepsis cases are hospital-acquired and current detection methods face timing challenges.
Zynex (NASDAQ: ZYXI) ha ottenuto il brevetto britannico 2617515 per un innovativo dispositivo multiparametrico non invasivo per il monitoraggio della sepsi. Questa tecnologia mira ad affrontare una crisi sanitaria globale critica, poiché la sepsi colpisce 1,7 milioni di persone ogni anno solo negli Stati Uniti e causa 11 milioni di decessi in tutto il mondo, con un terzo dei decessi ospedalieri attribuibili alla sepsi.
Il dispositivo monitorerà continuamente i segnali fisiologici per fornire avvisi precoci sullo stato di sepsi del paziente, sfruttando l'esperienza di Zynex nel monitoraggio cardiaco. La diagnosi precoce è fondamentale per il recupero del paziente, come sottolineato dalla Surviving Sepsis Campaign. Questa tecnologia potrebbe avere un impatto significativo sugli esiti del trattamento, soprattutto considerando che oltre il 50% dei casi di sepsi è acquisito in ospedale e che i metodi attuali di rilevamento presentano difficoltà temporali.
Zynex (NASDAQ: ZYXI) ha asegurado la patente del Reino Unido 2617515 para un novedoso dispositivo multiparamétrico no invasivo de monitoreo de sepsis. La tecnología busca abordar una crisis sanitaria global crítica, ya que la sepsis afecta a 1.7 millones de personas anualmente solo en EE.UU. y causa 11 millones de muertes a nivel mundial, con un tercio de las muertes hospitalarias relacionadas con sepsis.
El dispositivo monitoreará continuamente señales fisiológicas para proporcionar alertas tempranas sobre el estado de sepsis del paciente, aprovechando la experiencia de Zynex en monitoreo cardíaco. La detección temprana es crucial para la recuperación del paciente, como destaca la campaña Surviving Sepsis. Esta tecnología podría impactar significativamente los resultados del tratamiento, especialmente considerando que más del 50% de los casos de sepsis son adquiridos en hospitales y los métodos actuales enfrentan desafíos temporales.
Zynex (NASDAQ: ZYXI)는 새로운 다중 매개변수 비침습성 패혈증 모니터링 장치에 대해 영국 특허 2617515를 확보했습니다. 이 기술은 전 세계적으로 심각한 건강 위기를 해결하는 것을 목표로 하며, 미국에서만 매년 170만 명이 패혈증에 걸리고, 전 세계적으로 1100만 명이 사망하며, 병원 사망자의 3분의 1이 패혈증 관련입니다.
이 장치는 생리 신호를 지속적으로 모니터링하여 환자의 패혈증 상태에 대한 조기 경고를 제공하며, Zynex의 심장 모니터링 전문 지식을 활용합니다. 조기 발견은 환자 회복에 매우 중요하며, 이는 Surviving Sepsis Campaign에서도 강조됩니다. 이 기술은 특히 패혈증 사례의 50% 이상이 병원 내에서 발생하며 현재의 감지 방법이 시간적 한계에 직면해 있다는 점을 고려할 때 치료 결과에 큰 영향을 미칠 수 있습니다.
Zynex (NASDAQ : ZYXI) a obtenu le brevet britannique 2617515 pour un dispositif innovant de surveillance multiparamétrique non invasive de la septicémie. Cette technologie vise à répondre à une crise sanitaire mondiale majeure, la septicémie touchant 1,7 million de personnes chaque année aux États-Unis seulement et causant 11 millions de décès dans le monde, un tiers des décès hospitaliers étant liés à la septicémie.
Le dispositif surveillera en continu les signaux physiologiques pour fournir des alertes précoces sur l’état septique du patient, en s’appuyant sur l’expertise de Zynex en surveillance cardiaque. La détection précoce est cruciale pour la récupération du patient, comme le souligne la Surviving Sepsis Campaign. Cette technologie pourrait avoir un impact significatif sur les résultats du traitement, notamment sachant que plus de 50 % des cas de septicémie sont acquis à l’hôpital et que les méthodes actuelles de détection rencontrent des difficultés liées au timing.
Zynex (NASDAQ: ZYXI) hat das britische Patent 2617515 für ein neuartiges multiparametrisches, nicht-invasives Gerät zur Überwachung von Sepsis erhalten. Die Technologie zielt darauf ab, eine kritische globale Gesundheitskrise anzugehen, da Sepsis allein in den USA 1,7 Millionen Menschen jährlich betrifft und weltweit 11 Millionen Todesfälle verursacht, wobei ein Drittel der Krankenhaussterbefälle sepsisbedingt ist.
Das Gerät wird physiologische Signale kontinuierlich überwachen, um frühzeitige Warnungen über den Sepsisstatus des Patienten zu geben, und nutzt dabei die Expertise von Zynex im Bereich der Herzüberwachung. Früherkennung ist entscheidend für die Genesung des Patienten, wie von der Surviving Sepsis Campaign hervorgehoben. Die Technologie könnte die Behandlungsergebnisse erheblich verbessern, insbesondere da über 50 % der Sepsisfälle im Krankenhaus erworben werden und die aktuellen Erkennungsmethoden zeitliche Herausforderungen haben.
- Patent secured for innovative non-invasive sepsis monitoring technology
- Addresses large market opportunity with 1.7M annual US sepsis cases
- Potential to reduce mortality rates through early detection
- Leverages existing company expertise in cardiac monitoring
- Product still in development phase with no immediate revenue impact
- Will require additional regulatory approvals beyond patent
- Faces established competition in sepsis detection market
Insights
Zynex's UK patent for non-invasive sepsis detection represents significant potential in a large global market with high unmet medical need.
Zynex has secured an important intellectual property milestone with the award of UK patent 2617515 for a multiparameter, non-invasive sepsis monitor. This patent provides Zynex with protected technology rights in a critical medical area with substantial global impact. Sepsis affects at least 1.7 million Americans annually and is responsible for 11 million deaths globally, representing approximately 20% of all global deaths.
The technology aims to address a critical clinical challenge: early detection of sepsis. Current diagnostic methods often result in delayed treatment, which directly correlates with higher mortality rates. The company's approach leverages their existing expertise in cardiac monitoring to develop continuous physiological monitoring that could provide real-time alerts to clinicians.
This patent positions Zynex to potentially develop a highly differentiated product in the patient monitoring space. The sepsis monitoring market represents a substantial opportunity given the significant hospital presence of sepsis - responsible for 1 in 3 hospital deaths in the US. The technology's non-invasive approach would be a key advantage, potentially enabling broader and earlier use compared to invasive monitoring techniques.
The company appears to be strategically expanding its product portfolio beyond its core pain management devices into higher-acuity monitoring solutions. While the patent marks an important development milestone, investors should note that substantial product development, clinical validation, and regulatory approvals will likely be required before commercialization generates revenue from this technology.
Sepsis is a life-threatening condition characterized by systemic inflammation and organ dysfunction caused by an infection. Over half of sepsis cases are contracted in hospitals and have a high mortality rate due to the difficulty of early detection and diagnosis1. According to the Centers for Disease Control (CDC), at least 1.7 million people have sepsis each year in
"Sepsis is a global health crisis with a mortality rate among the highest of any medical issue," said Thomas Sandgaard, Founder and CEO of Zynex. "We have an opportunity to develop a noninvasive, highly accurate monitor that can provide real time information to clinicians that could help to drastically reduce this. We will develop this technology by leveraging our competencies of cardiac monitoring technologies."
This device is envisioned to continuously monitor multiple physiological signals to provide early alerts to clinicians about a patient's trends and sepsis status. The Surviving Sepsis Campaign, which is led by critical care physicians, has highlighted for decades that early detection and treatment is vital in ensuring a patient's recovery from sepsis4. Late diagnosis delays treatment, leading to a higher economic burden and increased mortality rates.
Donald Gregg, President of Zynex Monitoring Solutions, commented, "We believe that we can significantly contribute to the earlier detection of sepsis leading to a reduction in mortality from this deadly condition. This product would be derived from our growing portfolio of noninvasive monitoring technologies."
[1] Markwart R et al., Epidemiology and burden of sepsis acquired in hospitals and intensive care units: a systematic review and meta-analysis. Intensive Care Med. 2020. 46(8):1536-1551.
[2] About Sepsis. 2024. CDC: Sepsis. March 8, 2024. https://www.cdc.gov/sepsis/about/index.html.
[3] Sepsis. 2024. World Health Organization (WHO). May 3, 2024. https://www.who.int/news-room/fact-sheets/detail/sepsis
[4] Dellinger RP, et al., Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 2004. 32(3):858-73.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. our results of operations and the plans, strategies and objectives for future operations; the timing and scope of any potential stock repurchase; and other similar statements.
Words such as "anticipate," "believe," "continue," "could," "designed," "endeavor," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "seek," "should," "target," "preliminary," "will," "would" and similar expressions are intended to identify forward-looking statements. The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. The Company makes no express or implied representation or warranty as to the completeness of forward-looking statements or, in the case of projections, as to their attainability or the accuracy and completeness of the assumptions from which they are derived. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain CE marking of new products; the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources; the need to keep pace with technological changes; our dependence on the reimbursement for our products from health insurance companies; our dependence on first party manufacturers to produce our products on time and to our specifications' implementation of our sales strategy including a strong direct sales force, the impact of COVID-19 on the global economy; market conditions; the timing, scope and possibility that the repurchase program may be suspended or discontinued; economic factors, such as interest rate fluctuations; and other risks described in our filings with the Securities and Exchange Commission.
These and other risks are described in our filings with the Securities and Exchange Commission including but not limited to, our Annual Report on Form 10-K for the year ended December 31, 2024, as well as our quarterly reports on Form 10-Q and current reports on Form 8-K. Any forward-looking statements contained in this press release represent Zynex's views only as of today and should not be relied upon as representing its views as of any subsequent date. Zynex explicitly disclaims any obligation to update any forward-looking statements, except to the extent required by law.
About Zynex, Inc.
Zynex, founded in 1996, develops, manufactures, markets, and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for use in hospitals. For additional information, please visit: www.zynex.com.
Investor Relations Contact:
Dan Moorhead, CFO
ir@zynex.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/zynex-announces-award-of-uk-patent-for-non-invasive-detection-of-sepsis-302490592.html
SOURCE Zynex, Inc.
FAQ
What is the significance of Zynex's (ZYXI) new UK patent for sepsis detection?
How does Zynex's new sepsis monitoring technology work?
What is the market potential for Zynex's sepsis detection device?
When will Zynex's sepsis monitoring device be available commercially?
How does early sepsis detection impact patient outcomes?
